Plan includes products and services aimed at delivering tools for compound screening that meet the unique needs of academic investigators
Carl Zeiss MicroImaging, in collaboration with Cellomics, has announced plans to bring small molecule screening to basic science researchers supported by the US National Institutes of Health as part of the Molecular Libraries Screening Centers Network (MLSCN) and overall Molecular Libraries Initiative (MLI). A perfect balance of optical imaging technologies and screening expertise is offered through the partnership between Carl Zeiss and Cellomics, MLSCN research objectives including automation for target-based and cell-based phenotypic assay implementation, software for managing molecular library screening operations, and informatics tools for screening data management comprise the suite of tools that will speed the discovery of molecular research in the public sector.
High content screening has accelerated drug and research tool development in the pharmaceutical industry.
Automated fluorescence imaging and image analysis, data mining, compound management, screen quality control, and auditable screen development are among the suite of tools available to MLI investigators.
Cellomics's high content informatics (HCi) software platform is an integral part of this suite for compound screening and structure activity relationship (SAR) analyses.
"At the core of HCi is the Cellomics Store database, a highly scalable warehouse for assay protocols, images, and data that will enable screening center inter-operability" states Mark Collins, senior product manager for informatics at Cellomics.
"Carl Zeiss is pleased to be a partner with Cellomics.
"Between our two companies, we have a continuum of research tools for MLI investigators ranging from high resolution imaging to ultra-high throughput" commented James Sharp, president of Carl Zeiss MicroImaging and chairman of the board for Cellomics.
"Carl Zeiss, in partnership with Cellomics will bring many years of experience in screening within the Drug Discovery field to screening centers of the MLSCN," added Daniel Calvo, president and CEO of Cellomics.
